Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC
Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.
Related Articles
How Generalists Are Uniquely Positioned to Administer and Advance Oncology Care: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Dr. Sara Hurvitz receives the Smith Family Endowed Chair in Women’s Health
Fred Hutch Cancer Center Senior Vice President and Director of the Clinical Research Division Sara Hurvitz, MD, recently received the inaugural Smith Family Endowed Chair…
Durvalumab Shifts Decades Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC
Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.
Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor
R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.
Tumour hypoxia in driving genomic instability and tumour evolution
Nature Reviews Cancer – In this Review, Suvac et al. discuss how intratumoural hypoxia is a driving force in tumour evolution, alongside driver gene mutations,…
Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH
Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.
REZILIENT1 Trial Finds Zipalertinib Meets Primary End Point in EGFR+ NSCLC
The phase 2b REZILIENT1 trial of zipalertinib in EGFR+ non–small cell lung cancer met its overall response rate primary end point with a consistent safety…
Scientists Find Drug Combo Could Help Immune System Fight… : Oncology Times
An abstract is unavailable.
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
Guo et al. trace immune cell dynamics in patients with hepatocellular carcinoma (HCC) receiving neoadjuvant anti-PD-1 plus lenvatinib by single-cell multi-omics technologies. Compared with anti-PD-1 monotherapy,…
Episode 180: Reducing the Pain of Cancer Patients, with Dr. Whitney Luke
The James Cancer Hospital is a leader is helping cancer patients deal with the pain that can be associated with treatment. “Our inpatient oncology rehabilitation…
